Description: Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
cancer (3276) oncology (581) hematology (83) glioblastoma (29) protein therapeutics (6) oncological (3) hematological (3) malignant diseases (2) apg101 (2) phase ii trial (2)
This website was not optimized for Internet Explorer 8 and cannot be displayed correctly. For optimal navigation, please upgrade your browser or open the website in a different browser.
Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF -dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients.
>> More about COVID-19 >> More about immuno-oncology